Tags

Type your tag names separated by a space and hit enter

Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
J Clin Pathol. 2019 Aug; 72(8):542-549.JC

Abstract

AIMS

Limited information is available regarding the precise differences in the tumour immune microenvironment (TIM) of patients with human papilloma virus (HPV)-associated and non-HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Here, we retrospectively reviewed 137 patients with OPSCC treated with a definitive treatment to identify molecular relationships in the TIM.

MATERIALS AND METHODS

We used immunohistochemical analysis to assess p16 status, programmed death ligand 1 (PD-L1) level, and/or CD8+ tumour-infiltrating lymphocyte (TIL) density, followed by prognostic evaluation of these immune-related parameters.

RESULTS

Multivariate analyses demonstrated that PD-L1 level on immune cells but not on tumour cells or CD8+ TIL density was a significant predictive factor of disease-free survival (DFS) and overall survival (OS). Additionally, subgroup analyses demonstrated that patients positive for p16 and PD-L1 expression on immune cells had favourable DFS and OS, whereas patients negative for p16 and PD-L1 expression on immune cells showed worse DFS and OS.

CONCLUSIONS

We demonstrated that PD-L1 expression on immune cells but not tumour cells might represent a useful prognostic biomarker in patients with OPSCC receiving a definitive treatment. We propose that a co-assessment of p16 and PD-L1 expression on immune cells would have greater prognostic potential compared with evaluation of each factor alone in patients with OPSCC.

Authors+Show Affiliations

Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan ono123@med.kurume-u.ac.jp.Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.Department of Pathology, Omuta City Hospital, Omuta, Japan.Biostatistics Center, Kurume University School of Medicine, Kurume, Japan.Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31113825

Citation

Sato, Fumihiko, et al. "Prognostic Impact of P16 and PD-L1 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma Receiving a Definitive Treatment." Journal of Clinical Pathology, vol. 72, no. 8, 2019, pp. 542-549.
Sato F, Ono T, Kawahara A, et al. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol. 2019;72(8):542-549.
Sato, F., Ono, T., Kawahara, A., Kawaguchi, T., Tanaka, H., Shimamatsu, K., Kakuma, T., Akiba, J., Umeno, H., & Yano, H. (2019). Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. Journal of Clinical Pathology, 72(8), 542-549. https://doi.org/10.1136/jclinpath-2019-205818
Sato F, et al. Prognostic Impact of P16 and PD-L1 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma Receiving a Definitive Treatment. J Clin Pathol. 2019;72(8):542-549. PubMed PMID: 31113825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. AU - Sato,Fumihiko, AU - Ono,Takeharu, AU - Kawahara,Akihiko, AU - Kawaguchi,Toshihiko, AU - Tanaka,Hisaichiro, AU - Shimamatsu,Kazuhide, AU - Kakuma,Tatsuyuki, AU - Akiba,Jun, AU - Umeno,Hirohito, AU - Yano,Hirohisa, Y1 - 2019/05/21/ PY - 2019/03/01/received PY - 2019/04/06/revised PY - 2019/04/10/accepted PY - 2019/5/23/pubmed PY - 2019/7/30/medline PY - 2019/5/23/entrez KW - PD-L1 KW - head and neck cancer KW - oropharyngeal cancer KW - p16 SP - 542 EP - 549 JF - Journal of clinical pathology JO - J Clin Pathol VL - 72 IS - 8 N2 - AIMS: Limited information is available regarding the precise differences in the tumour immune microenvironment (TIM) of patients with human papilloma virus (HPV)-associated and non-HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Here, we retrospectively reviewed 137 patients with OPSCC treated with a definitive treatment to identify molecular relationships in the TIM. MATERIALS AND METHODS: We used immunohistochemical analysis to assess p16 status, programmed death ligand 1 (PD-L1) level, and/or CD8+ tumour-infiltrating lymphocyte (TIL) density, followed by prognostic evaluation of these immune-related parameters. RESULTS: Multivariate analyses demonstrated that PD-L1 level on immune cells but not on tumour cells or CD8+ TIL density was a significant predictive factor of disease-free survival (DFS) and overall survival (OS). Additionally, subgroup analyses demonstrated that patients positive for p16 and PD-L1 expression on immune cells had favourable DFS and OS, whereas patients negative for p16 and PD-L1 expression on immune cells showed worse DFS and OS. CONCLUSIONS: We demonstrated that PD-L1 expression on immune cells but not tumour cells might represent a useful prognostic biomarker in patients with OPSCC receiving a definitive treatment. We propose that a co-assessment of p16 and PD-L1 expression on immune cells would have greater prognostic potential compared with evaluation of each factor alone in patients with OPSCC. SN - 1472-4146 UR - https://www.unboundmedicine.com/medline/citation/31113825/Prognostic_impact_of_p16_and_PD_L1_expression_in_patients_with_oropharyngeal_squamous_cell_carcinoma_receiving_a_definitive_treatment_ L2 - https://jcp.bmj.com/lookup/pmidlookup?view=long&pmid=31113825 DB - PRIME DP - Unbound Medicine ER -